Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Open access
Le Deley, Marie-Cécile, Paulussen, Michael, Lewis, Ian, Brennan, Bernadette, Ranft, Andreas, Whelan, Jeremy, Le Teuff, Gwénaël, Michon, Jean, Ladenstein, Ruth, Marec-Bérard, Perrine, van den Berg, Henk, Hjorth, Lars, Wheatley, Keith, Judson, Ian, Juergens, Heribert, Craft, Alan, Oberlin, Odile, Dirksen, Uta · 2014 · Journal of Clinical Oncology

Abstract

Purpose: Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566). Methods: Standard-risk Ewing sarcomas were localized tumors with either a good histologic response to chemotherapy (< 10% cells) or small tumors (< 200 mL) resected at diagnosis or receiving radiotherapy alone as local treatment. Patients entered the trial after six VIDE+1 VAI courses. Allocated treatment was either 7 VAC courses with 1.5 g/m 2 of cyclophosphamide or seven VAI-courses with 6 g/m 2 ifosfamide. The limit of noninferiority was set at −8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in terms of the hazard ratio of event (HR event). Results: This large international trial recruited 856 patients between February 2000 and March 2010 (n = 431 receiving VAC and n = 425 receiving VAI). With a median follow-up of 5.9 years, the 3-year EFSs were 75.4% and 78.2%, respectively, the 3-year EFS difference was −2.8% (91.4% CI, −7.8 to 2.2%), the HR event was 1.12 (91.4% CI, 0.89 to 1.41), and the HR death was 1.09 (91.4% CI, 0.84 to 1.42; intention-to-treat). The HR event was 1.22 (91.4% CI, 0.96 to 1.54) on the per-protocol population. Major treatment modifications were significantly less frequent in the VAC arm (< 1%) than in the VAI arm (7%), mainly resulting from toxicity. Patients experienced more frequent thrombocytopenia in the VAC arm (45% v 35%) but fewer grade 2 to 4 acute tubular toxicities (16% v 31%). Conclusion: Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma. However, some uncertainty surrounding the noninferiority of VAC compared with VAI remains at this stage. The ongoing comparative evaluation of long-term renal and gonadal toxicity is crucial to decisions regarding future patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.54.4833

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 179

Metadata

Authors
Le Deley, M.-C., Paulussen, M., Lewis, I., Brennan, B., Ranft, A., Whelan, J., Le Teuff, G., Michon, J., Ladenstein, R., Marec-Bérard, P., van den Berg, H., Hjorth, L., Wheatley, K., Judson, I., Juergens, H., Craft, A., Oberlin, O., & Dirksen, U.
Venue
Journal of Clinical Oncology
Published
2014-08-10
Volume
32
Issue
23
Pages
2440-2448
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1973578742
Cited by
179
References
2
FWCI
13.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. https://app.cochat.ai/papers/10.1200/jco.2013.54.4833
The paper
Le Deley, M.-C., Paulussen, M., Lewis, I., Brennan, B., Ranft, A., Whelan, J., Le Teuff, G., Michon, J., Ladenstein, R., Marec-Bérard, P., van den Berg, H., Hjorth, L., Wheatley, K., Judson, I., Juergens, H., Craft, A., Oberlin, O., & Dirksen, U. (2014). Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.54.4833

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.